ABOUT US
公司介绍
四川泰恩康制药有限公司为广东泰恩康医药股份有限公司（股票代码：301263）全资子公司。公司成立于2020年09月29日，位于四川省岳池经济开发区，总占地面积100亩。拟投资建设建筑总面积约50000平方米，主要生产特色高附加值的各类原料药及中间体，如盐酸达泊西汀、他达拉非等产品，产能预计达300吨/年。
成立于2020年09月29日
总面积约50000平方米
产能预计达300吨/年
工艺研发
恩康用“真情”对待健康事业，以成为中国健康产业的引领者为目标，不仅是在企业业绩表现、社会责任、企业文化氛围等方面，为医药健康行业创造时代引领方向。
中式/验证生产
公司专注于研制开发全球卓越药品，其中以抗肿瘤药、抗感染、抗糖尿病、神经系统、肝胆系统用药为主要领域
质量研究
凭借公司管理研发团队对药物研发风险控制与GMP的深度了解和把握，开发出一系列值得信赖的药物制备工艺
中外双报
恩康用“真情”对待健康事业，以成为中国健康产业的引领者为目标，不仅是在企业业绩表现、社会责任、企业文化氛围等方面，为医药健康行业创造时代引领方向。
商业化供货
同时也积极与国际医药大公司合作推进新药研发业务，大力发展新药研发生产的高端技术工艺，努力开拓国际市场
cGMP体系标准
拟投资建设建筑总面积约50000平方米，主要生产特色高附加值的各类原料药及中间体，如盐酸达泊西汀、他达拉非等产品，产能预计达300吨/年。
视频中心
公司致力于推进一线药物产业化和创新药物研发，与国内一线药厂和研究机构开展了广泛的项目合作，同时也积极与国际医药大公司合作推进新药研发业务，大力发展新药研发生产的高端技术工艺，努力开拓国际市场。
R&D Center-Shandong Hubble Kisen
新闻中心
Taienkang will participate in CPHI – JAPAN 2024
Sichuan Taienkang Pharmaceutical Co., Ltd. will be participating as an exhibitor in the CPHI – JAPAN 2024 at Tokyo Big Sight, Tokyo, Japan.
22
2024-03
CKBA, an innovative drug of Taienkang, launched the Phase II clinical trials.
On Nov. 17th, 2023, the press conference on the Phase II Clinical Trial Protocol of Innovative Drug and the China Diagnosis and Treatment Consensus Seminar for the Treatment of Vitiligo Disease were held in Shanghai. At the meeting, Taienkang officiallly announced the launch of its CKBA vitiligo drug phase II clinical trial. The day before this day, a Taienkang's subsidiary company, BCY pharm, just completed the first examinee (the patient) enrollment for the Phase II clinical trial for the Class I innovative drug-CKBA (Saccinic Acid) ointment for the treatment of vitiligo.
21
2023-11
Sichuan Taienkang Pharmaceutical Co., Ltd attended the CPHI Worldwide 2023.
CPHI Worldwide 2023 was hold in Barcelona from Oct.24th to 26th . CPHI has held over 30 sessions and is the world's largest pharmaceutical industry professional exhibition, covering the entire supply chain of the pharmaceutical industry. Sichuan Taienkang Pharmaceutical Co., Ltd. attended this grand event as an exhibitor for the first time and advertised the products for APIs & intermediates, bio-generic drugs and FDFs. During the three-day exhibition, the company's products attracted many customers from all over the world, and the booth was bustling with visitors! In the future, Taienkang will take participating in such exhibitions as an opportunity to continuously strengthen communication and cooperation with customers, continuously improve product and service levels, actively expand overseas business, and strive to be a leading international pharmaceutical company.
27
2023-10
Scan QR code for mobile view
TEL.
ADD.
Manufacturing Site Address:
No. 22, Jiankang Road,
Economic Development Zone,
Yuechi County 638300,
Sichuan Province,
China.